Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A et al (2023) 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J Hypertens 41(12):1874–2071

Article  CAS  PubMed  Google Scholar 

Araujo-Castro M, Ruiz-Sánchez JG, Parra Ramírez P, Martín Rojas-Marcos P, Aguilera-Saborido A, Gómez Cerezo JF et al (2024) Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism. Vol. 85, Endocrine. Springer; pp. 99–121

Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH et al (2020) The unrecognized prevalence of primary aldosteronism a cross-sectional study. Ann Intern Med 173(1):10–20

Article  PubMed  PubMed Central  Google Scholar 

Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F et al (2017) Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice

Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC et al (2020) Genetics, prevalence, screening and confirmation of primary aldosteronism: A position statement and consensus of the working group on endocrine hypertension of the European society of hypertension ∗. J Hypertens 38(10):1919–1928

Article  CAS  PubMed  Google Scholar 

Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F et al (2018) Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 6(1):41–50

Article  CAS  PubMed  Google Scholar 

Resnick LM, Laragh JH Calcium Metabolism and Parathyroid Function in Primary Aldosteronism

Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, Verheyen N et al (2014) Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism 63(1):20–31

Wang A, Wang Y, Liu H, Hu X, Li J, Xu H et al (2022) Bone and mineral metabolism in patients with primary aldosteronism: A systematic review and meta-analysis. Frontiers in Endocrinology, vol 13. Frontiers Media S.A.

Google Scholar 

Shi S, Lu C, Tian H, Ren Y, Chen T (2020) Primary aldosteronism and bone metabolism: A systematic review and Meta-Analysis. Frontiers in Endocrinology, vol 11. Frontiers Media S.A.

Google Scholar 

Trandafir AI, Gheorghe AM, Sima OC, Ciuche A, Petrova E, Nistor C et al (2023) Cross-Disciplinary approach of adrenal tumors: insights into primary Aldosteronism-Related mineral metabolism status and osteoporotic fracture risk. International Journal of Molecular Sciences, vol 24. Multidisciplinary Digital Publishing Institute (MDPI)

Google Scholar 

Rossi E, Perazzoli F, Negro A, Sani C, Davoli S, Dotti C et al (1998) Acute Effects of Intravenous Sodium Chloride Load on Calcium Metabolism and on Parathyroid Function in Patients With Primary Aldosteronism Compared With Subjects With Essential Hypertension [Internet]. Vol. 11, AJH. Available from: https://academic.oup.com/ajh/article/11/1/8/164981

Wu VC, Chang CH, Wang CY, Lin YH, Kao TW, Lin PC et al (2017) Risk of fracture in primary aldosteronism: A Population-Based cohort study. J Bone Miner Res 32(4):743–752

Article  CAS  PubMed  Google Scholar 

Notsu M, Yamauchi M, Yamamoto M, Nawata K, Sugimoto T (2017) Primary aldosteronismas a risk factor for vertebral fracture. J Clin Endocrinol Metab 102(4):1237–1243

Article  PubMed  Google Scholar 

Kim BJ, Kwak MK, Ahn SH, Kim H, Lee SH, Koh JM (2018) Lower trabecular bone score in patients with primary aldosteronism: human skeletal deterioration by aldosterone excess. J Clin Endocrinol Metab 103(2):615–621

Article  PubMed  Google Scholar 

Araujo-Castro M, Paja Fano M, González Boillos M, Pla Peris B, Pascual-Corrales E, García Cano AM et al (2022) Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO registry. Endocrine 76(3):687–696

Article  CAS  PubMed  Google Scholar 

Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H et al (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(5):1889–1916

Article  CAS  PubMed  Google Scholar 

Monticone S, Sconfienza E, D’Ascenzo F, Buffolo F, Satoh F, Sechi LA et al (2020) Renal damage in primary aldosteronism: A systematic review and meta-analysis. Journal of Hypertension, vol 38. Lippincott Williams and Wilkins, pp 3–12

Google Scholar 

Giustina A, Bilezikian JP, Adler RA, Banfi G, Bikle DD, Binkley NC et al (2024) Consensus statement on vitamin D status assessment and supplementation: whys, whens, and hows. Endocr Rev 45(5):625–654

Gómez-Ramírez J, Mihai R (2017) Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm. Langenbecks Arch Surg 402(7):1103–1108

Article  PubMed  Google Scholar 

Silva BC, Cusano NE, Bilezikian JP (2018) Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab 32(5):593–607

Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GEH, Marcocci C, Minisola S et al (2022) Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. Vol. 37, Journal of Bone and Mineral Research. John Wiley and Sons Inc; pp. 2293–314

Parra Ramírez P, Martín Rojas-Marcos P, Paja Fano M, González Boillos M, Peris BP, Pascual-Corrales E et al (2024) Is adrenal venous sampling always necessary to differentiate between unilateral and bilateral primary aldosteronism? Lesson from the SPAIN-ALDO register. Endocrine 84(2):683–693

Article  PubMed  Google Scholar 

Gravvanis C, Papanastasiou L, Glycofridi S, Voulgaris N, Tyfoxylou E, Theodora K et al (2021) Hyperparathyroidism in patients with overt and mild primary aldosteronism. Hormones 20(4):793–802

Article  PubMed  Google Scholar 

Kometani M, Yoneda T, Aono D, Gondoh-Noda Y, Matsuoka T, Higashitani T et al (2021) Primary aldosteronism with parathyroid hormone elevation: A single-center retrospective study. Intern Med 60(7):993–998

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang Y, Zhang C, Ye L, Su T, Zhou W, Jiang L et al (2016) Factors affecting parathyroid hormone levels in different types of primary aldosteronism. Clin Endocrinol (Oxf) 85(2):267–274

Article  CAS  PubMed  Google Scholar 

Brunaud L, Germain A, Zarnegar R, Rancier M, Alrasheedi S, Caillard C et al (2009) Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery 146(6):1035–1041

Article  PubMed  Google Scholar 

Brown JM, Williams JS, Luther JM, Garg R, Garza AE, Pojoga LH et al (2014) Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension 63(2):273–280

Article  CAS  PubMed  Google Scholar 

Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG (2001) PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells [Internet]. Available from: http://www.ajpendo.org

Asbach E, Bekeran M, Reincke M (2015) Parathyroid gland function in primary aldosteronism. Hormone and Metabolic Research, vol 47. Georg Thieme, pp 994–999

Google Scholar 

Iglesias P, Arias J, López G, Romero I, Díez JJ (2023) Primary hyperparathyroidism and cardiovascular disease: an association study using clinical natural Language processing systems and big data analytics. J Clin Med 12(21):6718

Zheng MH, Li FXZ, Xu F, Lin X, Wang Y, Xu QS et al (2020) The interplay between the Renin-Angiotensin-Aldosterone system and parathyroid hormone. Frontiers in Endocrinology, vol 11. Frontiers Media S.A.

Google Scholar 

Hagström E, Michaëlsson K, Melhus H, Hansen T, Ahlström H, Johansson L et al (2014) Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community-based cohorts. Arterioscler Thromb Vasc Biol 34(7):1567–1573

Article  PubMed  Google Scholar 

Walker MD, Silverberg SJ (2008) Cardiovascular aspects of primary hyperparathyroidism. J Endocrinological Invest Editrice Kurtis S R L 31:925–931

Article  CAS  Google Scholar 

Luigi P, Chiara FM, Laura Z, Cristiano M, Giuseppina C, Luciano C et al (2012) Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: Preliminary results. Int J Endocrinol.;2012

Tomaschitz A, Pilz S, Rus-Machan J, Meinitzer A, Brandenburg VM, Scharnagl H et al (2015) Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. Int J Cardiol 184(1):710–716

Article  PubMed  Google Scholar 

Devidi M, Buddam A, Dacha S, Rao DS, Disclosures None Corresponding Author: Atrial Fibrillation and Its Association with Endocrine Disorders [Internet]. Available from: www.jafib.com

Rienstra M, Lubitz SA, Zhang ML, Cooper RR, Ellinor PT (2011) Elevation of parathyroid hormone levels in atrial fibrillation. J Am Coll Cardiol 57:2542–2543

Article  PubMed  PubMed Central  Google Scholar 

Zavatta G, Clarke BL, Normocalcemic Hyperparathyroidism (2020) A heterogeneous disorder often misdiagnosed?? Vol. 4, JBMR plus. Blackwell Publishing Ltd

Google Scholar 

Shaker JL, Wermers RA (2023) The eucalcemic patient with elevated parathyroid hormone levels. J Endocr Soc 7(4):bvad013

Calvo MS, Eastell R, Offord KP, Bergstralh EJ, Burritt MF Circadian Variation in Ionized Calcium and Intact Parathyroid Hormone: Evidence for Sex Differences in Calcium Homeostasis. J Clin Endocrinol Metab [Internet]. 1991 Jan 1 [cited 2024 Oct 6];72(1):69–76. Available from: https://nebulosa.icesi.edu.cohttps://doi.org/10.1210/jcem-72-1-69

Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C et al (2017) Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5(9):689–699

Article  PubMed  PubMed Central  Google Scholar 

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A (2018) Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 6(1):51–59

Article  PubMed  Google Scholar 

Wachtel H, Fraker DL (2021) Therapeutic outcomes with surgical and medical management of primary aldosteronism. Current Cardiology Reports, vol 23. Springer

Google Scholar 

Ahmed S, Hundemer GL (2022) Benefits of surgical over medical treatment for unilateral primary aldosteronism. Frontiers in Endocrinology, vol 13. Frontiers Media S.A.

Google Scholar 

Rossi GP, Ragazzo F, Seccia TM, Maniero C, Barisa M, Calò LA et al (2012) Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension 60(2):431–436

Article  CAS  PubMed  Google Scholar